Live: 100 Years of Innovation in Insulin Therapy

    Monday, March 22, 2021
    Program: 5:30 PM – 7:00 PM EDT  

    Join us for a discussion of:

    • Transforming Diabetes Care Through Insulin 
    • Where Are We Now, and How Did We Get Here? Impact of Insulin Evolution on Clinical Practice 
    • The Future of Insulin Therapy

    This course is a virtual live CME-certified Ancillary Symposium developed in collaboration with our partner - Institute for Medical and Nursing Education (IMNE), to be presented at ENDO 2021. This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc. This ancillary symposium is developed through the Endocrine Society’s Special Programs Committee (SPC).




    • CLAIM CME 



    Learning Objectives

    Upon successful completion these educational sessions, participants should be better able to:

    • List innovations in insulin therapy over the past 100 years and their impact on practice
    • Recognize indications for initiation and/or advancement of insulin therapy for people with T2D
    • Describe the range of insulin therapies and their potential benefits for individualizing treatment for people living with diabetes
    • Discuss recent data on newer and emerging basal and prandial insulins, and insulin technology, and implications on treatment approaches for people living with diabetes

    Additional Information

    Target Audience: 
    Clinical researcher
    Scientific researcher
    Nurse/Nurse practitioner
    Physician assistant
    Allied health professional
    Competency Area: 
    Medical Knowledge
    Topic Area: 
    Diabetes and Glucose Metabolism
    Level of Outcomes: 
    Level 1 (Participation)
    Level 2 (Satisfaction)
    Level 3A (Learning: Declarative Knowledge (Knows))
    Level 3B (Learning: Procedural Knowledge (Knows How))
    Level 4 (Learning: Competence (Shows How))
    Activity summary
    Available credit: 
    • 1.50 ABIM MOC
    • 1.50 AMA PRA Category 1 Credits
    • 1.50 CME Certificate of Participation
    Course opens: 
    Course expires: 

    5:30 – 5:35 PM | Introduction, Pre-Test Polling | Anne Peters, MD

    5:35 – 5:55 PM | Where Are We Now, and How Did We Get Here? Impact of Insulin Evolution on Clinical Practice | Vanita R. Aroda, MD

    5:55 – 6:25 PM | Where Are We Now, and How Did We Get Here? Transforming Diabetes Care Through Insulin Technology | Carol J. Levy, MD, CDCES

    6:25 – 6:45 PM | What Does the Future Hold? | Wendy S. Lane, MD

    6:45 – 7:00 PM | Closing Remarks, Post-Test Polling, Q&A Session | All Faculty"


    Anne Peters, MD
    Professor of Clinical Medicine
    Keck School of Medicine
    Director, University of Southern California
    Los Angeles, CA

    Vanita R. Aroda, MD
    Director, Diabetes Clinical Research
    Division of Endocrinology, Diabetes & Hypertension
    Brigham and Women’s Hospital
    Faculty, Harvard Medical School
    Boston, MA

    Wendy S. Lane, MD
    Clinical Endocrinologist
    Director of Clinical Research
    Mountain Diabetes & Endocrine Center
    Asheville, NC

    Carol J. Levy, MD, CDCES
    Associate Professor of Medicine, Department of Endocrinology, Diabetes and Bone Disease
    Associate Professor, Department of Obstetrics, Gynecology and Reproductive Science
    Director, Mount Sinai Diabetes Center and Type 1 Diabetes Clinical Research
    Icahn School of Medicine at Mount Sinai
    New York, NY


    As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.


    The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

    The following faculty reported relevant financial relationships:
    Anne Peters, MD: Advisory Board Member, Abbott Laboratories, Eli Lilly & Company, Lilly USA, LLC, Mannkind Corporation, Merck & Co., Novo Nordisk, Zealand Pharmaceuticals; Grant Recipient, Abbott Laboratories, Dexcom; Other, Teledoc, Omada Health
    Vanita R. Aroda, MD: Consultant, Applied Therapeutics, Novo Nordisk, Pfizer, Inc., Sanofi;Spouse, employee Merck, Janssen Research & Development Company; Research Investigator, Applied Therapeutics, Eli Lilly & Company, Fractyl Laboratories, Novo Nordisk, Sanofi; Spouse, Stock Owner Merck, Janssen Research & Development Company.
    Wendy S. Lane, MD: Advisory Board Member, Novo Nordisk; Consultant, Xeris Pharmaceuticals; Grant Recipient, Novo Nordisk; Research Investigator, Novo Nordisk; Speaker, Novo Nordisk, Xeris Pharmaceuticals, Dexcom
    Carol J. Levy, MD, CDCES: Advisory Board Member, Dexcom, Eli Lilly & Company; Grant Recipient, Abbott Diabetes; Research Investigator, Insulet Corporation, Dexcom

    The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:  Beret Anne Casey, MD

    The following SPC Committee members reported financial relationships:

    • Andjela T. Drincic, MD: Advisory Board Member, Corcept
    • Sergio Fazio, MD, PhD: Consultant, Amarin, Amgen, Akcea, Aegerion, Esperion, Novartis
    • Angela M. Leung, MD: Speaker, Medical Education Resources, MCE Conferences, ATA Board Member
    • Amy Rothberg, MD: Spouse, consultant of Merck
    • Katherine Araque, MD: Speaker, Novo Nordisk; Advisory Board, Corcept

    The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

    The following SPC members reported no relevant financial relationships:

    Lorena Alarcon-Casas Wright, MD, Neena Natt, MD; Kelly Lauter Roszko, MD, PhD; Deborah Sellmeyer, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD

    The Endocrine Society and IMNE staff associated with the development of this CME activity reported no relevant financial relationships.



    The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.


    When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.


    The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


    The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.


    This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc.

    The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    AMA PRA Category 1 Credit:

    The Endocrine Society designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

    Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

    Maintenance of Certification (MOC):

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Available Credit

    • 1.50 ABIM MOC
    • 1.50 AMA PRA Category 1 Credits
    • 1.50 CME Certificate of Participation